BTK inhibitor

SAN CARLOS, Calif. | May 29, 2026 BeOne Medicines presented groundbreaking long-term data at the 2026 American Society of...

BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...

SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...

BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...

BEIJING, April 29, 2026 InnoCare Pharma has announced that the first patient has been dosed in the registrational Phase...

PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...

Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...

Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...

Dateline — WALTHAM, Mass., November 11, 2025:Zenas BioPharma, Inc. (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company dedicated to developing...

INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...